An interventional study of B-Crobes intake complete nutrition and Placebo in Breast Cancer Early Stage Breast Cancer (Stage 1-3) and Mastectomy Patient, sponsored by University of Malaya. Recruiting at 1 site in Malaysia. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-26.
Sponsored by University of Malaya · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Breast Neoplasms with a site in Malaysia — 14 open to participants now, 27 under way, 19 of them phase 3. Breast Neoplasms · Malaysia.
Among the 62 studies in Breast Neoplasms with a site in Malaysia, this one is the 47th largest by planned enrollment of the 59 interventional ones that give a count, is one of 4 that started in 2025, is one of 13 with no phase, reaches primary completion later than 9 of the 26 other live ones, and was the 58th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →14 of the 62 studies in Breast Neoplasms with a site in Malaysia are open now. Recruiting first, the newest first:
BeOne Medicines · Sites in Malaysia, United States, Australia and 13 more countries
Ages 18+
Olema Oncology, Inc. · Sites in Malaysia, United States, Australia and 21 more countries
Ages 18+
Celcuity Inc · Sites in Malaysia, United States, Argentina and 22 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Malaysia, United States, Argentina and 38 more countries
Ages 18+
National University of Malaysia · Sites in Malaysia
Ages 18–65 · Women only
A study can be open while its sites in Malaysia have not opened yet or have stopped. Only those recruiting at a site in Malaysia →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 35
First in 1996; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 114 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 479 across the 59 interventional studies, 1,151 across the 1 observational. Of the 28 that completed or were terminated, 21 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 62 have an industry lead sponsor. The 10 most frequent:
University of Malaya is the lead sponsor of 285 studies on the registry; 59 are open to participants now.
University of Malaya has 4 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
6 of the studies in Breast Neoplasms with a site in Malaysia that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04208178Phase 3Novartis PharmaceuticalsStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | 2027-02-26 |
| NCT05774951Phase 3AstraZenecaA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | 2027-04-20 |
| NCT06312176Phase 3Merck Sharp & Dohme LLCA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | 2027-07-11 |
| NCT04862663Phase 3AstraZenecaCapivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) | 2027-11-01 |
| NCT05315700ORIC PharmaceuticalsStudy of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 62 studies in Breast Neoplasms with a site in Malaysia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to measure the mean difference of phase angle after nutritional intervention in breast cancer patients. The main question it aims to answer is:
Researchers will compare oral nutritional supplement to a placebo to see if oral nutritional supplement can improve phase angle.
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo
Dietary Supplement: Placebo
Oral nutrition supplement
Dietary Supplement: B-Crobes intake complete nutrition
Contains whey and plant based proteins, enriched with prebiotics and probiotics, Ca-Hmb, minerals and multivitamins.
Also known as: Oral nutrition supplement
Contains full cream dairy milk
Mean difference of phase angle after nutritional intervention
To measure the mean difference of phase angle between groups after nutritional intervention
Time frame: From enrollment to 30 days post operation
Changes in handgrip strength
To study the changes on handgrip strength, body composition by bioimpedance analysis (skeletal muscle mass, skeletal muscle mass index, fat free mass and fat mass) after nutritional interventions.
Time frame: From enrollment to 30 days post operation
Correlation of phase angle with bioimpedance analysis parameters
To describe the correlation of phase angle with nutritional status, handgrip strength, and body compositions by bioimpedance analysis (Skeletal muscle mass, skeletal muscle mass index, fat free mass, and fat mass).
Time frame: From enrollment to 30 days post operation
Potential factors associated with postoperative complications
To identify the potential factors associated with complications and readmission in 30-days post-mastectomy participants.
Time frame: From enrollment to 30 days post operation
Cutoff value of phase angle
To identify the cutoff value of PA in relation to GLIM malnutrition, nutrition risk, and sarcopenia
Time frame: From enrollment to 30 days post operation
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Oct 2026, 19 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 19 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.